当前位置： SCI文献检索 > EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING期刊下所有文献 > CSF p-tau/Aβ42 ratio and brain FDG-PET may reliably detect MCI "imminent" converters to AD.

CSF p-tau/Aβ42 ratio and brain FDG-PET may reliably detect MCI "imminent" converters to AD.

Abstract：

PURPOSE:To know whether mild cognitive impairment (MCI) patients will develop Alzheimer's disease (AD) dementia in very short time or remain stable is of crucial importance, also considering new experimental drugs usually tested within very short time frames. Here we combined cerebrospinal fluid (CSF) AD biomarkers and a neurodegeneration marker such as brain FDG-PET to define an objective algorithm, suitable not only to reliably detect MCI converters to AD dementia but also to predict timing of conversion. METHODS:We included 77 consecutive MCI patients with neurological/neuropsychological assessment, brain 18F-FDG-PET and CSF analysis available at diagnosis and a neuropsychological/neurological evaluation every 6 months for a medium- to a long-term follow-up (at least 2 and up to 8 years). Binomial logistic regression models and Kaplan-Meier survival analyses were performed to determine the best biomarker (or combination of biomarkers) in detecting MCI converters to AD dementia and then, among the converters, those who converted in short time frames. RESULTS:Thirty-five out of 77 MCI patients (45%) converted to AD dementia, with an average conversion time since MCI diagnosis of 26.07 months. CSF p-tau/Aβ42 was the most accurate predictor of conversion from MCI to AD dementia (82.9% sensitivity; 90% specificity). CSF p-tau/Aβ42 and FDG-PET-positive MCIs converted to AD dementia significantly earlier than the CSF-positive-only MCIs (median conversion time, 17.1 vs 31.3 months). CONCLUSIONS:CSF p-tau/Aβ42 ratio and brain FDG-PET may predict both occurrence and timing of MCI conversion to full-blown AD dementia. MCI patients with both biomarkers suggestive for AD will likely develop an AD dementia shortly, thus representing the ideal target for any new experimental drug requiring short periods to be tested for.

journal_name

Eur J Nucl Med Mol Imaging

journal_title

European journal of nuclear medicine and molecular imaging

authors

Santangelo R,Masserini F,Agosta F,Sala A,Caminiti SP,Cecchetti G,Caso F,Martinelli V,Pinto P,Passerini G,Perani D,Magnani G,Filippi M

doi

10.1007/s00259-020-04853-4

subject

Has Abstract

pub_date

2020-12-01 00:00:00

pages

3152-3164

issue

eissn

1619-7070

issn

1619-7089

pii

10.1007/s00259-020-04853-4

journal_volume

pub_type

杂志文章

在线工具

CSF p-tau/Aβ42 ratio and brain FDG-PET may reliably detect MCI "imminent" converters to AD.